Print
Email
Print Edition StoriesThursday, December 31, 2009
Decision Biomarkers in Ch. 7 bankruptcy filing
By Mass High Tech staff
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
Decision Biomarkers Inc., a Waltham-based protein biomarker analysis developer, has reported that it has closed its doors and made a Chapter 7 filing in U.S. Bankruptcy Court.
The filing was submitted December 22 according to federal documents, and the DBI website notes “as of December 2, 2009 DBI will be closing its doors...There are several companies interested in the technology and we are hopeful the business will be reconstituted in the near future.”
Decision Biomarkers lists its total estimated assets in a range between $0 to $50,000, while its total liabilities ranged from $1 million to $10 million. Following payment of administrative expenses, company officials do not expect to have sufficient funds for its unsecured creditors; the bankruptcy filing lists DBI’s number of creditors between 50 to 99.
Decision Biomarkers was formerly known as Clinical Microarrays Inc.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
